Research Atlas · source screening

Bortezomib

An attributable first-pass index of PubMed records whose titles name this governed identity. Records are sorted by publication date, not by evidence strength. Inclusion does not establish efficacy, safety, or a clinical indication.

Scope: Single-source, name-in-title discovery sample. Not a systematic review, worldwide source coverage, clinical appraisal, efficacy or safety conclusion, or complete WPF profile. This source index is separate from the Public Peptide Directory and from human observations.

Title-search results: 4,835
Shown with stable PMIDs: 25
Search recorded: 2026-09-26

Source: NCBI PubMed / MEDLINE · exact query: "Bortezomib"[Title] · up to 25 recent title matches per identity. Each result links to its PubMed record.

A fast method for the quantification of bortezomib in serum and rat nervous tissue by liquid chromatography tandem mass spectrometry.
J Pharm Biomed Anal · 2026 Dec 15 · PMID 42526316 · DOI 10.1016/j.jpba.2026.117686
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Selinexor combined bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma with high-risk factors: a single-arm, multi-center, prospective observational clinical study.
Ann Med · 2026 Dec · PMID 42544613 · DOI 10.1080/07853890.2026.2703403
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Frequency-adjusted daratumumab-based regimen versus bortezomib/dexamethasone in newly diagnosed AL amyloidosis: a matched-cohort study.
Ann Med · 2026 Dec · PMID 41560662 · DOI 10.1080/07853890.2026.2617767
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Palbociclib in combination with dexamethasone, bortezomib, and doxorubicin for pediatric relapsed acute lymphoblastic leukemia.
Blood Neoplasia · 2026 Nov · PMID 42668671 · DOI 10.1016/j.bneo.2026.100276
Source metadata only · evidence grade unassigned · scientific conclusions pending review
tRNA-derived fragment tRF-17-8SPOL52 induces resistance to bortezomib in multiple myeloma via autophagy activation.
Biochim Biophys Acta Mol Basis Dis · 2026 Nov · PMID 42551544 · DOI 10.1016/j.bbadis.2026.168396
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUS.
J Clin Oncol · 2026 Sep 25 · PMID 42789828 · DOI 10.1200/JCO-26-00401
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Upamostat potentiates bortezomib cytotoxicity and delays proteasome recovery in bortezomib-resistant malignant lymphoma cells through modulation of the DDI2/NRF1 axis.
Biochim Biophys Acta Mol Cell Res · 2026 Sep 22 · PMID 42772524 · DOI 10.1016/j.bbamcr.2026.120224
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Inducing oxidative stress by targeting the cholesterol biosynthesis pathway augments the efficacy of bortezomib in multiple myeloma.
Free Radic Biol Med · 2026 Sep 21 · PMID 42767467 · DOI 10.1016/j.freeradbiomed.2026.09.019
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Economic advantage of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: A cost-per-responder evaluation.
J Manag Care Spec Pharm · 2026 Sep 11 · PMID 42726291 · DOI 10.18553/jmcp.2026.26127
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Pomalidomide plus bortezomib and dexamethasone for newly diagnosed multiple myeloma with renal impairment: Randomized phase II study (POM-MM-003).
Med · 2026 Sep 9 · PMID 42716009 · DOI 10.1016/j.medj.2026.101293
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial.
Lancet Oncol · 2026 Sep 7 · PMID 42705255 · DOI 10.1016/S1470-2045(26)00286-X
Source metadata only · evidence grade unassigned · scientific conclusions pending review
A Phase Ib Case Series Using Bortezomib With Chemotherapy in Atypical Teratoid/Rhabdoid Tumors.
Cancer Med · 2026 Sep · PMID 42745490 · DOI 10.1002/cam4.72173
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Triptonide enhances DNA damage by inhibiting TRIP13‑mediated DNA repair and synergizes with bortezomib to suppress multiple myeloma.
Int J Oncol · 2026 Sep · PMID 42464653 · DOI 10.3892/ijo.2026.5919
Source metadata only · evidence grade unassigned · scientific conclusions pending review
When All Else Fails: Complete Remission with Bortezomib in a Child with Life-Threatening Refractory Autoimmune Hemolytic Anemia.
Turk J Haematol · 2026 Sep 1 · PMID 42460765 · DOI 10.4274/tjh.galenos.2026.94763
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Successful Bortezomib-Lenalidomide-Dexamethasone Therapy in a 72-Year-Old Patient With Sporadic Late-Onset Nemaline Myopathy Associated With Monoclonal Gammopathy of Muscle Significance.
Muscle Nerve · 2026 Sep · PMID 42429161 · DOI 10.1002/mus.70342
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma.
Br J Haematol · 2026 Sep · PMID 42403116 · DOI 10.1111/bjh.70642
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell Lymphoma.
Am J Hematol · 2026 Sep · PMID 42305039 · DOI 10.1002/ajh.70406
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Comparative Efficacy of Belantamab Mafodotin in Combination With Bortezomib and Dexamethasone Versus Standards of Care in Patients With Third-Line or Later Relapsed/Refractory Multiple Myeloma.
Am J Hematol · 2026 Sep · PMID 42286808 · DOI 10.1002/ajh.70408
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Belantamab mafodotin, bortezomib, and dexamethasone for RRMM in the Japan expansion cohort of the phase 3 DREAMM-7 trial.
Int J Hematol · 2026 Sep · PMID 41986580 · DOI 10.1007/s12185-026-04211-4
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Pomalidomide, bortezomib and dexamethasone in multiple myeloma refractory to lenalidomide and anti- CD38 monoclonal antibodies: outcomes from a real-world experience.
Haematologica · 2026 Sep 1 · PMID 41885018 · DOI 10.3324/haematol.2025.289143
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Real-world outcomes of daratumumab, bortezomib, thalidomide and dexamethasone (Dara-VTd) induction and lenalidomide maintenance in transplant-eligible multiple myeloma.
Br J Haematol · 2026 Aug 27 · PMID 42657531 · DOI 10.1111/bjh.70775
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Daratumumab-bortezomib-cyclophosphamide-dexamethasone for newly diagnosed amyloidosis: ANDROMEDA final survival analysis.
Blood · 2026 Aug 27 · PMID 42118698 · DOI 10.1182/blood.2025032099
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Comparison of bortezomib with dexamethasone and thalidomide with dexamethasone in the treatment of patients with monoclonal immunoglobulin deposition disease.
J Nephrol · 2026 Aug 24 · PMID 42634194 · DOI 10.1093/joneph/aajag144
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Bortezomib.
Journal not recorded · 2012 · PMID 31643359
Source metadata only · evidence grade unassigned · scientific conclusions pending review
Early First-Line Bortezomib for Acute Antibody-Mediated Rejection: A Retrospective Review of Long-Term Outcomes From a Uniform Single-Center Protocol.
Transplant Proc · 2026 Aug 19 · PMID 42618412 · DOI 10.1016/j.transproceed.2026.07.032
Source metadata only · evidence grade unassigned · scientific conclusions pending review

Loading research intelligence

Preparing the structured Flagship evidence library.